Emgality ‘CONQUER’s in late-stage migraine trial
Treatment with Emgality reduced monthly migraine headache days by 4.1 days.
Read More
Tag: galcanezumab
Lilly’s Emgality wins first nod for migraine prevention
The US Food and Drug Administration have green-lighted use of Eli Lilly’s non-opioid pain drug Emgality for the prevention of migraine.
Read More
CHMP puts 13 therapies forward for EU approval
Marking a bumper month for Committee for Medicinal Products for Human Use (CHMP) decisions, 13 medicines have been put forward for approval in the region, including three orphan medicines.
Read More
Mixed trial results for Lilly’s headache drug galcanezumab
Lilly has reported mixed trial data for its experimental therapy galcanezumab, showing efficacy in patients with episodic cluster headaches but failing in those with chronic cluster headache.
Read More
Lilly files anti-CGRP drug for migraine
US regulators have accepted for review Eli Lilly’s investigational non-opioid pain drug galcanezumab for the prevention of migraine.
Read More
Triple trial boost for Lilly’s migraine drug
CGRP treatment galcanezumab looks to be course for regulatory submissions
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
